Management of Hypothyroidism Management of adult hypothyroidism requires therapy Table 1 : Initiating treatment
|
|
- Ezra Clark
- 7 years ago
- Views:
Transcription
1 SUPPLEMENT TO JAPI JANUARY 2011 VOL Management of Hypothyroidism in Adults Nikhil Tandon Screening for Hypothyroidism Routine screening for hypothyroidism in asymptomatic persons few expert panels have suggested that screening may be A beneficial in high-risk patients such as in elderly women. Widespread screening is unlikely to be cost-effective and given the non-specific symptoms of hypothyroidism, many patients will nevertheless be tested. However, asymptomatic screening should not be confused with this practice. Screening is recommended for the following high risk groups: All newborn infants (mandatory in many states) Downs syndrome Pregnant women with or without goiter Have a strong family history of thyroid disease A personal history of thyroid dysfunction Have an autoimmune disease, such as Type 1 Diabetes Are taking lithium Have Depression Have elevated lipid levels Are found to have a thyroid nodule The American Thyroid Association (ATA) recommends routine screening at 35 years of age and subsequently after every 5 years. The recommendations of other professional bodies such as The American Association of Clinical Endocrinologist (AACE), American Academy of Family Physicians (AAFP), and The American College of Physician (ACP) vary with each other and with those of ATA. Patients in the high-risk category are: Those aged over 60. Those with a history of thyroid disease, thyroid surgery or radiation to the neck Those with a history of heart disease, particularly with atrial fibrillation Those with other autoimmune diseases. 1 Management of Hypothyroidism Management of adult hypothyroidism requires therapy Table 1 : Initiating treatment Patient population Thyroxine treatment Healthy adult patients with require thyroid hormone hypothyroidism replacement in a dosage of 1.7 μg per kg per day Elderly 1μg per kg per day Children may require up to 4μg per kg per In young patients without risk factors for cardiovascular disease In patients at risk for the cardiovascular compromise day Levothyroxine therapy should be started at a dosage of mg per day and should be titrated against increasing serum TSH levels with small gradual increments. Thyroid hormone replacement therapy should be started at a dosage of mg per day, which should be gradually increased by to mg every four to six weeks until TSH levels are normalized. Professor, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi with levothyroxine (L-thyroxine). Orally administered L-thyroxine is well absorbed (~80% intestinal absorption; predominantly jejunal), more so in the fasted than fed state. Differences in bioavailability have been reported between different brands. Hence, it is advisable not to alter the brand during chronic therapy. Serum T4 concentrations peak 2 to 4 hours after an oral dose and remain above normal for approximately 6 hours in patients receiving daily replacement therapy. The long half-life of thyroxine of about 7 days allows treatment with a single daily tablet. There is limited utility of using L-triiodothyronine for replacement, because adequate T3 levels are generated by conversion in patients on L-thyroxine therapy. L-triiodothyronine, which has a short t/2 of approximately 24 hours, has some times been recommended for the management of patients with thyroid cancer to shorten the period of hypothyroidism required for diagnosis and treatment of remaining tumor tissue with 131 I. 2 Replacement with thyroxine As mentioned above, therapy with L-thyroxine is the preferred mode of providing thyroid hormone replacement, on account of its long half-life, ease of absorption, availability of multiple tablet strengths and the absence of any clearly documented benefits of additional T3 replacement. Thyroxine supplementation therapy is recommended to be administered as a single daily dose, half-an-hour to one hour prior to breakfast (Table 1). A minimum gap of 4 hours should be maintained between administration of thyroxine and drugs that are known to interfere with its absorption. The rapidity with which normal thyroid hormone levels should be restored is dictated by several factors, notably, the age of patient, the duration and severity of the hypothyroidism, and the presence or absence of other co-morbid conditions, specifically cardiac disease. In healthy young adults, the complete replacement dose of 1.6 to 1.8µg levothyroxine/kg ideal body weight can be started immediately. The etiology of hypothyroidism may also influence the replacement dose, such that patients with total thyroidectomy or severe primary hypothyroidism have slightly higher requirements than do patients who become hypothyroid after radioiodine or surgical treatment for Graves disease, who may retain some residual thyroid function. In the absence of any functioning thyroid tissue, the complete daily replacement dose in women and men ranges from 100 and 150µg and between 125 and 200µg respectively. Full replacement doses should not be administered initially to patients over the age of 60, to patients who have a history of coronary artery disease, or to patients with long-standing severe hypothyroidism. This cautious approach is advisable to prevent precipitation of angina in people with underlying coronary heart disease or agitation and anxiety which can occasionally occur in patients with long-standing severe hypothyroidism exposed to the complete replacement dose. In such patients, the dose should be titrated, starting with 25µg a day and increased by increments of 25µg at 8-week-intervals until serum TSH falls to normal. If however, angina is precipitated while increasing thyroxine dose, the dose should be reduced to the highest dose tolerated by the patient, and a further attempt made to increase the dose again only after another 4 weeks. After initiating therapy, the dose should be monitored by assessing serum TSH (with or without serum T4) after at least 2 months, the minimum time required for the pituitary-thyroid
2 22 SUPPLEMENT TO JAPI JANUARY 2011 VOL. 59 Table 2 : Initiation and monitoring of treatment for hypothyroidism Yes Start levothyroxine, to 0.05 mg per day. Yes Is there a need for documenting thyroid hormone replacement? Is the patient > 50 years of age and/or at risk for cardiac disease? Does the patient still have lethargy or memory problems? No Start levothyroxine mg per day TSH level (if primary hypothyroidism) or free T4 level (if secondary hypothyroidism) to be monitored every 6 to 8 weeks; adjust dosage of levothyroxine until laboratory tests are normal. Consider adding triiodothyronine, mg per day (although long-term effects are not known). axis to re-set after introducing therapy or making a dose adjustment (Table 2). If the serum TSH is within the normal range, ideally keeping a serum TSH target of approximately 2-3 miu/l, the same dose of thyroxine can be continued. In the event that the serum TSH is either elevated or suppressed, there will be need for a modest increase or decrease in dose respectively. The dose should ideally not be increased or decreased by more than 12.5 or 25µg, and serum TSH again measured after two months to assess adequacy of the dose. Once the patient attains a biochemical euthyroid state, serum TSH should next be measured after 6 months. This is required because at initiation of therapy, due to the hypothyroid state, the administered thyroxine may be still be metabolized slowly and appear adequate for the patient s requirements. Once euthyroidism is restored, thyroxine metabolism may increase and the same dose be rendered sub-optimal. Once a stable thyroxine dose is achieved, monitoring needs to be carried out on an annual basis. While this strategy works for most patients with hypothyroidism, patients with post-ablative hypothyroidism may continue to have a decline in thyroid reserve over the years, necessitating semi-annual or even annual dose changes till the effect of the radio-iodine plateaus. Sometimes a similar evolution of declining thyroid reserve over a period of time may also be observed in patients with Graves disease who have had a sub-total thyroidectomy. Some experts also estimate serum T4 (total or free) to monitor therapy. If this is being done, care should be taken that the blood sample should be collected prior to receiving the day s dose of thyroxine. Invariably if the serum TSH levels are in the mid to low normal range, serum T4 levels will be in the mid to high normal range. For obvious reasons, the main role of serum T4 is when monitoring thyroxine replacement in a patient with central hypothyroidism. Clinical response: The earliest clinical response to thyroxine replacement is usually diuresis and weight loss, due to mobilization of fluid. Weight loss consequent to decrease in fat is usually minimal and late in the course of response. After weight loss, the other features which improve are appetite, constipation, No Continue to monitor TSH or T 4 levels annually hoarseness of voice, and much later the cold intolerance and fatigue. Treatment failures: The commonest cause for an inadequate response is poor compliance, which is not unusual with any chronic therapy. Most patients when questioned appropriately will accept the missing of doses. If the index of suspicion for non-compliance is high, it sometimes helps to confront the patient with the question How many doses did you miss last month half or one-third or one-fourth? than to ask Did you miss any dose in the last month? The following observations are clues for non-compliance: unexpectedly high thyroxine requirement, normal free T4 with elevated TSH, erratic and inexplicable serial thyroid function test readings. It sometimes helps to ask the patient to take a week s supply of medicine in a separate pill-box, which will allow easy ascertainment of missed doses. Any extra pills left in the container can actually be taken on the last day of the week, to ensure that the patient receives his or her weekly dose. Weekly dosing or end of week catch up dosing while sub-optimal remains an acceptable alternative in patients who have been seen to be habitual non-compliers. If despite these measures TSH levels do not reach the target value, co-existing conditions or treatment which may interfere with either thyroxine absorption or metabolism should be checked. Special situations Pregnancy: A special situation which needs discussion in detail is the thyroxine replacement in pregnancy, which is probably related maximally to the increase in serum TBG. Patients on thyroxine replacement should report to their physician the moment pregnancy is confirmed, to allow a bi-monthly monitoring of TSH levels, and appropriate dose adjustments. The mean increment in the required daily thyroxine dose is 50µg; which is usually apparent by the end of the first trimester, though may be delayed to as late as the 6 th month of gestation in some women. A similar up-titration of thyroxine dose may be required in women who are on estrogen preparations including the oral contraceptive pill. Hypocortisolemia: In the event there is co-existence of thyroid hormone deficiency and glucocorticoid deficiency it is important to replace glucocorticoid before starting thyroxine. This is so because thyroxine therapy may lead to an increased metabolism, and thereby an increased demand, of cortisol, potentially increasing the likelihood of precipitating an adrenal crisis. Central hypothyroidism: This should be dealt with similar to the patient with co-existent hypocortisolism, in that the glucocorticoid replacement should be initiated prior to thyroxine replacement. Monitoring of therapy should be done with serum T4 levels instead of serum TSH levels, for which the sample should be collected prior to ingesting the morning dose of thyroxine. Ischemic heart disease: As discussed above, while thyroxine therapy improves myocardial function and reduces peripheral vascular resistance, it also increases the myocardial oxygen demand. This may precipitate angina, which has been reported in 2% of patients in large series of hypothyroid individuals being initiated on thyroxine replacement. Hence, patients with preexisting angina should ideally undergo a cardiac evaluation prior to initiating thyroxine therapy. As already detailed above, therapy in such individuals should be started at 25µg/day or even less and increased no faster than at 4 weekly intervals. Patients unable to take oral thyroxine: If patients are unable to take oral thyroxine for prolonged periods of time, intravenous thyroxine can be given in a dose approximately 70% of the oral
3 SUPPLEMENT TO JAPI JANUARY 2011 VOL dose, which reflects the fractional absorption of the oral dose. 3 Drug interactions The clinician must be aware of important interactions with antacids as well as iron formulations. Concurrent use of these drugs may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Calcium carbonate and ferrous sulphate form insoluble chelate and a ferric-thyroxine complex respectively. Therefore, these drugs should be taken at least 4 hours apart from levothyroxine. Important clinical pointers when monitoring thyroid replacement therapy Serial TSH measurements can be used to determine the adequacy of treatment with thyroid hormones in patients with an intact hypothalamic-pituitary axis. It is important to keep in mind that changes in TSH levels lag behind changes in thyroid hormone levels. Subsequent to adjustment of levothyroxine dosage, TSH levels should be assessed only at least after four weeks. Changes in TSH levels become completely apparent only after eight weeks of therapy with thyroid hormone replacement. The adequacy of treatment in patients with pituitary insufficiency can be gauged by measurements of free T 4 and T 3 levels. The target of treatment is to maintain the patient euthyroid with free thyroid hormone levels in the middle to upper ranges of normal. Most hypothyroid patients are tested annually for TSH or free T 4 levels, although no data exists to support this practice. It is generally known that when a stable maintenance dosage of levothyroxine is achieved, it is adequate to maintain a euthyroid state until the patient becomes 6o to 70 years old. Increasing age is associated with declining thyroid binding and serum albumin levels. In such patients, the dosage requirement may need to be reduced by up to 20%. Elderly patients should undergo annual monitoring for thyroid function in order to avoid over replacement. Less frequent monitoring can be justified in younger patients who have stable weight. Persistently elevated TSH despite thyroid hormone replacement The most frequent reason for persistent elevation of serum TSH levels in patients presumed to be receiving adequate thyroid replacement therapy is poor compliance. Some patients, who do not take their replacement medication regularly, try to catch up when a physician visit approaches. In such settings, the free T 4 levels may be restored to normal; however, they continue to have elevated TSH levels. Tissue-level unresponsiveness to thyroid hormone is rare, and is caused by mutation in the gene that controls a receptor for T 3, rendering it unable to bind with the hormone. Only 300 families have been identified with this genetic mutation. Such patients have adequate levels of thyroid hormones that are ineffective, leading to persistent elevation of TSH and continuation of symptoms. For further evaluation and proper management, such patients should be referred to an endocrinologist. 4 Drugs potentially altering thyroid hormone replacement requirements Increase replacement requirements Drugs that reduce thyroid hormone production Lithium Iodine-containing medications Amiodarone Drugs that reduce thyroid hormone absorption Sucralfate Ferrous sulfate Cholestyramine Colestipol Aluminium-containing antacids Calcium products Drugs that increase metabolism of thyroxine Rifampin Phenobarbital Carbamazepine Warfarin Oral hypoglycaemic agents Increase thyroxine availability and may decrease replacement requirements Drugs that displace thyroid hormone from protein binding Furosemide Mefenamic acid Salicylates Potential adverse effects of treatment: Regular monitoring of serum TSH levels to ensure mid-normal serum TSH values ensures that life-long replacement therapy with thyroxine is safe and free from adverse events. In the event that thyroxine is being given in suppressive doses, as used after carcinoma thyroid surgery, there are several potential adverse effects especially involving the skeletal and cardiovascular system. A TSH value of 0.1mU/l, has been identified as a risk factor for the development of atrial fibrillation, and is also associated with left ventricular hypertrophy and enhanced risk for ischemic heart disease. Sub-clinical thyrotoxicosis consequent to an inappropriately high dose of thyroxine, especially in postablated post-menopausal patients with Graves disease has been associated with bone loss. Treatment of Myxedema Coma: Myxedema coma is a severe life threatening situation which is more often reported in winter in the setting of sepsis, cerebrovascular accidents, congestive heart failure or inappropriate drug therapy e.g. overzealous diuretic use for hypertension and edema resulting in hyponatremia, sedatives, and anti-depressants. The common clinical manifestations, in addition to the peripheral features of severe hypothyroidism include respiratory depression, bradycardia, hypotension, decreased intestinal motility, hyponatremia, altered sensorium, infections and hypothermia. These are specifically listed here because they need individual attention to ensure recovery of a patient from myxedema coma. All patients must be admitted to the intensive care unit and ventilatory support initiated. Most patients need ventilatory support for at least hours, and during this period frequent measurement of arterial blood gases is mandatory. The endotracheal tube should be retained till the patient is fully conscious. In case the patient is not intubated care of the upper airway should be performed with diligence. In case of hyponatremia, fluid restriction and judicious use of small volume of saline or dextrose saline is usually adequate if serum sodium is > 120mEq/L. If serum sodium falls < 120mEq/L, hypertonic saline followed by intravenous furosemide to promote water diuresis may be needed. Warmth should be ensured but this
4 24 SUPPLEMENT TO JAPI JANUARY 2011 VOL. 59 Table 3 : Conditions requiring adjustment of thyroxine Conditions requiring adjustment of the replacement dose of thyroxine for hypothyroidism. Increased dose requirement Decreased intestinal absorption of T4 Malabsorption (e.g. celiac disease); short bowel syndrome Atrophic gastritis, infection with H pylori Dietary fiber supplements; bran Drugs: aluminium hydroxide (used as an antacid), ferrous sulfate, calcium carbonate, omeprazole (and other proton pump inhibitors) Increased need for T4 Weight gain Pregnancy Increased clearance of T4 Phenobarbital, phenytoin, carbamazepine, rifampicin, valproate, imatinib, sunitinib Unknown mechanism Amiodarone, sertraline, chloroquine Decreased dose requirement Decreased need for T4 Weight loss Androgens Decreased clearance of T4 Old age Proposed Interventions Change in dose till the malabsorption syndrome is rectified Treat primary condition Alter time of high fiber supplement Alter time of ingestion of iron, aluminium Decrease dose Decrease dose should be done cautiously or else the resultant peripheral vasodilatation may cause hypotension. Hypotension should be corrected by judicious administration of dextrose saline or if hyponatremia is present then normal saline. Most physicians also prefer covering the first few days with intravenous hydrocortisone (50-100mg every 6 to 8 hours) to tackle the impaired adrenal reserve which may manifest when thyroxine therapy is initiated. Thyroid hormone therapy in patients with myxedema coma: This is a matter of continuing debate especially with regards to use of T3, dose, rapidity of correction and route of administration. While advocates of T3 therapy refer to its shorter half life and faster onset of action, most centres use T4 therapy which has a longer half life, with a likelihood of smoother control. The preferred route of administration is intravenous, with different experts suggesting doses varying from µg as the initial loading dose, followed by µg given daily. The high initial bolus probably helps restore the extra-thyroidal pool of T4, and also allows for generating adequate T3 levels by peripheral conversion. If intravenous T3 is selected, its proponents give 10-20µg followed by 10µg every 6 hours for a day or two. Some centres combine parenteral T4 and T3 using the following regimen: 4 micrograms per kg T4 bolus, followed by 100 micrograms daily thereafter; and a concurrent 10µg bolus of T3 along with 10µg every 8-12 hours after that. Once the patient has an improved sensorium, has normal bowel activity and is accepting orally patient can be shifted back to oral thyroxine replacement. However, in India, intravenous thyroxine is not readily available and most institutions give crushed thyroxine tablets through the nasogastric tube in place of parenteral therapy. The initial dose given is usually µg followed by 100µg daily thereafter. This route is suboptimal and not only are there concerns of erratic absorption, especially in patients with gastric atony, but also the increased risk of aspiration unless the airway is protected. The interventions mentioned above can only serve as guidelines because each patient manifests with their unique clinical problems which need individualized care (Table 3). However, all the facets mentioned above must be dealt with comprehensively to improve the prognosis. Subclinical Hypothyroidism While screening patients for thyroid disease, physicians often find increased thyrotropin-stimulating hormone (TSH) levels in patients whose free thyroxine (T 4 ) levels are not below normal. Subclinical hypothyroidism, characterized by persistently elevated TSH levels and free thyroxine (T 4 ) levels are not below normal, most commonly precedes overt hypothyroidism. In some patients, the condition may resolve on its own or remain unchanged. Rest of the patients proceed to develop overt hypothyroidism (low free T 4 and raised TSH levels) within a few years. Patients with larger TSH elevations and detectable anti-thyroid antibody levels are at increased risk of developing overt disease. Patients with subclinical hypothyroidism may have mild hypothyroid symptoms and may have subtle serum lipoprotein and cardiac function abnormalities. Therefore, in patients with definite and persistent elevation of TSH, thyroid replacement therapy should be considered. Progression to overt hypothyroidism occurs at a rate of 5 to 20% per year in patients with both mildly elevated TSH levels and antithyroid antibodies. Clinical manifestations, if present, may be explained by assuming that a T 4 level of 6 or 7µg/dl (77 to 90nmol/L), although not outside the normal range of 4.5 to 12.5µg per dl (58 to 160nmol/L), may represent a significant fall from an original level of 9 or 10µg/dl (116 to 129nmol/L) and, thus, is low for this particular patient. The preferred therapy for patients with subclinical hypothyroidism is levothyroxine at a dosage that maintains normal TSH levels. Treatment of Subclinical Hypothyroidism Patients with subclinical hypothyroidism, because of the minimal extent of the thyroid hormone deficiency, may be controlled with total daily dosages of levothyroxine as low as 25 to 50µg (Table 4). This initial dosage should be maintained for six to eight weeks before a TSH measurement is repeated to guide adjustment of the levothyroxine dosage. The goal is to maintain the TSH level within normal limits; the dosage of levothyroxine should be increased if the TSH level remains above normal and should be decreased if the TSH level falls below normal. The frequency of TSH assessment can be reduced to every 6 to 12 months after establishing an appropriate maintenance dosage. A common error is the failure to decrease the levothyroxine dosage if the TSH level is suppressed below the normal range, which may occur without the free T 4 level rising above normal. Subclinical hyperthyroidism, characterized by suppressed TSH levels without a rise in free T 4 levels, is believed to cause undesirable effects on bone density (osteoporosis), cardiac function, and neuropsychologic symptoms together with causing other mild manifestations of hyperthyroidism. 5
5 SUPPLEMENT TO JAPI JANUARY 2011 VOL Table 4 : Treatment of subclinical hypothyroidism TSH > 10µU/ml Check antithyroid antibodies In presence of normal T4 levels, TSH is higher than normal after two tests 6 weeks apart Positive Negative No symptoms Therapy with levothyroxine Symptoms present that might be associated with hyperthyroidism Therapy T 4=thyroxine; TSH=thyrotropin-stimulating hormone TSH between 5-10 µu/ml Antibodies +ve or symptoms present Consider therapy Antibodies ve, no symptoms Observe and retest every 6 months Resistance to thyroid hormones Reduced responsiveness of target tissues to thyroid hormone or resistance to thyroid hormones (RTH) occurs due to mutations in the thyroid hormone receptor b gene. The syndrome occurs as a rare autosomal dominant inherited syndrome of reduced end-organ responsiveness to thyroid hormone. Presentation Two forms of RTH have been described on the basis of the associated clinical features: generalized resistance (GRTH) and pituitary resistance (PRTH). In GRTH, patients are asymptomatic with few clinical signs while in PRTH, patients present with some signs and symptoms associated with thyrotoxicosis. According to a literature review, a wide overlap of symptoms and signs is seen in individuals with GRTH and PRTH. Biochemical and physiologic assessments of thyroid hormone action are useful, but limited owing to the lack of precision and overlap of values seen in GRTH and PRTH. Moreover, significant temporal variation in clinical signs and parameters of thyroid hormone action in the same individual with no correlation with subjective symptoms has been observed. Thyroid hormone levels Patients with RTH have elevated serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations Normal or slightly elevated serum thyroid stimulating hormone (TSH) level. Clinical implications Many patients with RTH have tachycardia, goiter and elevated serum thyroid hormone levels, causing them to be misdiagnosed as cases of Grave s disease. Almost one-thirds of such patients are receiving inappropriate treatment. When a patient presents with elevated thyroid hormone level and normal or slightly increased TSH levels (SITSH), the diagnosis of RTH should be kept in mind. Several patients have been treated with TRIAC therapy. TSH-secreting pituitary adenomas and the presence of endogenous anti-thyroxine antibodies and antitriiodothyronine antibodies constitute the differential diagnoses. Nearly one-third patients of RTH have been treated inappropriately due to failure to differentiate RTH from primary thyrotoxicosis. No specific treatment is available for RTH, although it is desirable. However, the correct diagnosis allows for proper genetic counseling. It is now possible to differentiate between RTH and other diseases with similar laboratory results (high T4 with normal TSH) such as familial dysalbuminemia or antiiodothyronine antibodies or TSH antibodies due to the availability of new assays for free thyroid hormones. In patients with thyrotoxic symptoms, familial occurrence and a normal TSH-response to TRH that cannot be suppressed by T3 are characteristic features of RTH that may help in differentiating between RTH and TSH-secreting pituitary tumours. The presence of thyrotoxicosis suggests PRTH while absence of thyrotoxicosis is seen in GRTH Non responders to levothyroxime supplements In patients who are poor responders or inadequate responders to thyroxine supplements, the clinician may consider changing the brand of thyroxine.this may help in improved bioavailability of thyroxine Conclusion The treatment of adult hypothyroidism requires replacement with L-thyroxine. The full replacement dose of L-thyroxine in adults is 1.6 to 1.8µg levothyroxine/kg/day. Replacement can be started with the full dose in a healthy young adult. However, caution needs to be exercised in the elderly (age more than 60 years), and in people with co-morbidities like ischemic heart disease or hypocortisolism. In the elderly and those suspected to have ischemic heart disease, therapy should be initiated at the dose of 25µg and increased only at 4 weekly intervals. In patients with co-existent hypocortisolism, glucocorticoid replacement should precede thyroxine replacement. Non-compliance, conditions which interfere with absorption or metabolism of thyroxine or changes in drug clearance necessitate dose changes. Exposure to excess thyroxine has a negative impact on cardiac and skeletal health and should be avoided at all costs. Myxedema coma is a life threatening condition which requires aggressive critical care management in addition to judicious use of parenteral thyroxine therapy. References 1. American Academy of Pediatrics. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006;117: Hueston WJ. Treatment of Hypothyroidism. Am Fam Physician. 2001;15; 64(10): Adlin Victor. Subclinical Hypothyroidism: Deciding When to Treat. Am Fam Physician.1998; 57(4): Beck-Peccoz P, Chatterjee VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid. 1994; 4: Chatterjee VK. Resistance to thyroid hormone--an uncommon cause of thyroxine excess and inappropriate TSH secretion. Acta Med Austriaca. 1994;21(2): Olateju TO, Vanderpump MP. Thyroid hormone resistance. Ann Clin Biochem. 2006;43: Yamada M. Resistance to thyroid hormone. Nippon Rinsho. 2006;64(12): Woeber KA. Treatment of hypothyroidism. In The Thyroid: A fundamental and Clinical Text eds L E Braverman, R D Utiger. Lippincott Williams and Wilkins, 2007; Wilmar Wiersinga. Adult hypothyroidism. In Thyroid Disease Manager (
optimal use of thyroid function tests (TFTs) to diagnose and monitor thyroid disease.
Guidance for Thyroid Function Testing in Primary Care in Lothian In July 2006 following a lengthy consultation process, a joint working group comprising representatives from the Association of Clinical
More informationThyroid Dysfunction in the Elderly. Rund Tahboub, MD University Hospitals Case Western Reserve University
Thyroid Dysfunction in the Elderly Rund Tahboub, MD University Hospitals Case Western Reserve University Outline Normal thyroid physiology, regulation and action Changes in thyroid function with aging
More informationGuidelines for the Use of Thyroid Function Tests. Grey s Hospital Laboratory. Pietermartizburg Complex. Compiled and adapted by
Guidelines for the Use of Thyroid Function Tests Grey s Hospital Laboratory Pietermartizburg Complex Compiled and adapted by Dr. R. Sirkar Chemical Pathologist UKZN August 2006 Compiled and Adapted by
More informationThyroid Disorders. Hypothyroidism
1 There are a number of problems associated with the thyroid gland. Hypothyroidism, hyperthyroidism, and thyroid nodules will be presented here. The thyroid gland is located in the middle of the neck,
More informationHypothyroidism clinical features and treatment. 1. The causes of hypothyroidism
Hypothyroidism clinical features and treatment 1. The causes of hypothyroidism The thyroid is a gland in the neck which makes two thyroid hormones, thyroxine (T4) and tri-iodothyronine (T3). Thyroxine
More informationUK Guidelines for the Use of Thyroid Function Tests (July 2006)
Adapted Summary of UK Guidelines for the Use of Thyroid Function Tests (July 2006) Introduction The Use of Thyroid Function Tests Guidelines Development Group was formed in 2002 under the auspices of the
More informationHypothyroidism and Depression: Use of TSH as a Diagnostic Tool and the Role of Thyroid Supplement Therapy in Psychiatric Practice
Hypothyroidism and Depression: Use of TSH as a Diagnostic Tool and the Role of Thyroid Supplement Therapy in Psychiatric Practice By Scott McDonald, DO PGY1 Hypothyroidism General medicine texts always
More informationHypothyroidism. Written by Donald Yung Edited by Dianna Louie. Basic Embryology and Anatomy
Hypothyroidism Written by Donald Yung Basic Embryology and Anatomy The thyroid gland consists of two lobes connected by an isthmus and is located anterior to the trachea at the base of the neck. During
More informationThyroid Gland Disease. Zdeněk Fryšák 3rd Clinic of Internal Medicine Nephrology-Rheumatology-Endocrinology Faculty Hospital Olomouc
Thyroid Gland Disease Zdeněk Fryšák 3rd Clinic of Internal Medicine Nephrology-Rheumatology-Endocrinology Faculty Hospital Olomouc t 1/2 = 5-7d t 1/2 = < 24 hrs Normal Daily Thyroid Secretion Rate:
More informationRECOMMENDATIONS. INVESTIGATION AND MANAGEMENT OF PRIMARY THYROID DYSFUNCTION Clinical Practice Guideline April 2014
INVESTIGATION AND MANAGEMENT OF PRIMARY THYROID DYSFUNCTION Clinical Practice Guideline April 2014 OBJECTIVE Alberta clinicians optimize laboratory testing for the investigation and management of primary
More informationloving life YOUR GUIDE TO YOUR THYROID
loving life YOUR GUIDE TO YOUR THYROID one THE THYROID two HYPOTHYROIDISM three HYPERTHYROIDISM four TREATING HYPERTHYROIDISM five THYROID NODULES AND GOITRES one THE THYROID What is the thyroid? The thyroid
More informationTHYROID FUNCTION TESTS
Thyroid Stimulating Hormone (TSH): THYROID FUNCTION TESTS The thyroid stimulating hormone (TSH) assay measures the concentration of thyroid stimulating hormone in the serum. TSH assays have been classified
More informationTSH. TSH is an integral part of a thyroid panel useful for the determination and potential differentiation of hypothyroidism.
TSH Background Thyroid hormone synthesis and secretion is regulated via a negative feed-back control system, which involves the hypothalamus, anterior pituitary, and the thyroid gland. Thyrotrophin-releasing
More informationEverything You Ever Wanted to Know About the Thyroid
Everything You Ever Wanted to Know About the Thyroid (but were afraid to ask ) Caroline Messer, MD Board Certified Internist, Endocrinologist, and Physician Nutrition Specialist Topics Thyroid Nodules
More informationGUIDELINES & PROTOCOLS
GUIDELINES & PROTOCOLS ADVISORY COMMITTEE Effective Date: January 1, 2010 Scope This guideline applies to: the detection of thyroid dysfunction in adults (individuals 19 years of age and over) monitoring
More informationOrdering and interpreting thyroid tests in children. Paul Kaplowitz, MD, PhD Children s National Medical Center, Washington, DC
Ordering and interpreting thyroid tests in children Paul Kaplowitz, MD, PhD Children s National Medical Center, Washington, DC Objectives To review indications for thyroid testing To discuss which tests
More informationA Parent s Guide to Understanding Congenital Hypothyroidism. Children s of Alabama Department of Pediatric Endocrinology
A Parent s Guide to Understanding Congenital Hypothyroidism Children s of Alabama Department of Pediatric Endocrinology How did you get here? Every baby born in the state of Alabama is required by law
More informationAdrenal Insufficiency. Adrenal cortex secretions. Adrenal Insufficiency. Adrenal Insufficiency. Acute Adrenal Insufficiency
Adrenal cortex secretions Cortisol secretion Diurnal pattern 24 hour secretion = Stress = demands 30 mg 300 mg to meet physiological Adrenal Insufficiency PRIMARY ADDISON S DISEASE Autoimmune Infection
More informationPregnancy and hypothyroidism
Pregnancy and hypothyroidism Departments of Endocrinology & Obstetrics Patient Information What What is hypothyroidism? is hypothyroidism? Hypothyroidism means an underactive thyroid gland, which does
More informationTHYROID DISEASE IN CHILDREN
THYROID DISEASE IN CHILDREN Douglas G. Rogers, M.D. Center for Pediatric and Adolescent Endocrinology Cleveland Clinic Foundation Unfortunately neither I nor any immediate family members have any financial
More informationParents Guide To Primary Congenital Hypothyroidism
Parents Guide To Primary Congenital Hypothyroidism California Department of Health Services Genetic Disease Branch www.dhs.ca.gov/gdb To Parents: California State Law requires that all babies have the
More informationAutoimmune Thyroid Disorders. Register at www.srlknowledgeforum.com
Autoimmune Thyroid Disorders Register at www.srlknowledgeforum.com 1 What is AITD? Autoimmune thyroid disease (AITD) is a common organ specific autoimmune disorder seen mostly in women between 30-50 yrs
More informationGuidance for Preconception Care of Women with Thyroid Disease
Before, Between & Beyond Pregnancy The National Preconception Curriculum and Resources Guide for Clinicians Guidance for Preconception Care of Women with Thyroid Disease Avi Alkalay, MD Department of Obstetrics
More informationThyroid Hormone Replacement
Thyroid Hormone Replacement Name: Levothyroxine is the generic name for all thyroid hormone that replaces T4. Recommended Brand names are Synthroid and Levoxyl What is levothyroxine? Levothyroxine is synthetic
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationLothian Guidance for Diagnosis and Management of Thyroid Dysfunction in Pregnancy.
Lothian Guidance for Diagnosis and Management of Thyroid Dysfunction in Pregnancy. Early diagnosis and good management of maternal thyroid dysfunction is essential to ensure minimal adverse effects on
More informationNHS FORTH VALLEY Thyroid Storm
NHS FORTH VALLEY Thyroid Storm Date of First Issue 01 August 2006 Approved 01 August 2006 Current Issue Date 1 st July 2016 Review Date 1 st July 2018 Version EQIA Yes 01/08/2010 Author / Contact Group
More informationANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for
More informationThyroid-Stimulating Hormone (TSH)
Thyroid-Stimulating Hormone (TSH) Table of Contents Test Overview Why It Is Done How To Prepare How It Is Done How It Feels Risks Results What Affects the Test What To Think About References Credits Test
More informationLaboratory evaluation of thyroid function
FEATURE: LAURA M. GUNDER, DHSC, MHE, PA-C, AND SARA HADDOW, MSA, PA-C Laboratory evaluation of thyroid function Blood tests can detect thyroid dysfunction, which can result in cardiac, GI, and menstrual
More informationShort Synacthen Test for the Investigation of Adrenal Insufficiency
Pathology at the Royal Derby Hospital Short Synacthen Test Standard Clinical Guidelines Chemical Pathology Department Valid Until 31 st March 2015 Document Code: CHISCG1 Short Synacthen Test for the Investigation
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationVitamin D Deficiency and Thyroid Disease. Theodore C. Friedman, M.D., Ph.D.
Vitamin D Deficiency and Thyroid Disease Theodore C. Friedman, M.D., Ph.D. Vitamin D deficiency and thyroid diseases Vitamin D is an important vitamin that not only regulates calcium, but also has many
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2016 2/2017 2/2016 Description of Procedure or Service Vitamin D,
More informationDisability Evaluation Under Social Security
Disability Evaluation Under Social Security Revised Medical Criteria for Evaluating Endocrine Disorders Effective June 7, 2011 Why a Revision? Social Security revisions reflect: SSA s adjudicative experience.
More informationManagement of Clients with Thyroid and Parathyroid Disorders
Management of Clients with Thyroid and Parathyroid Disorders Black, J.M. & Hawks, J.H. (2005) Chapters 45, (pp 1191-1216) 1216) Baptist Health School of Nursing NSG 4037: Adult Nursing III Carole Mackey,
More informationGraves disease in childhood Antithyroid drug therapy
83rd Annual Meeting of the ATA October 620, 203 Duration of antithyroid drugs treatment Disclosure Nothing to disclose Pr Juliane Léger Paediatric Endocrinology Department Paris Diderot University Hôpital
More informationHYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
More informationACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
More informationPreconception Clinical Care for Women Medical Conditions
Preconception Clinical Care for Women All women of reproductive age are candidates for preconception care; however, preconception care must be tailored to meet the needs of the individual. Given that preconception
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationICD-9-CM/ICD-10-CM Codes for MNT
/ Codes for MNT ICD (International Classification of Diseases) codes are used by physicians and medical coders to assign medical diagnoses to individual patients. It is not within the scope of practice
More informationClassification of thyroid disorders
Hypothalamus TRH Hypophyse TSH Thyroïde T3 T4 Organes cibles T3 Foie Classification of thyroid disorders T3, T4 overt hyperthyroidism subclin. hyperthyroidism normal values sublin. hypothyroidism overt
More informationPHENYLEPHRINE HYDROCHLORIDE INJECTION USP
PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada
More informationATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
More informationGoiter. This reference summary explains goiters. It covers symptoms and causes of the condition, as well as treatment options.
Goiter Introduction The thyroid gland is located at the base of your neck. If the gland becomes abnormally enlarged, it is called a goiter. Goiters usually do not cause pain. But a large goiter could cause
More informationA publication of the American Thyroid Association (ATA) www.thyroid.org
HYPOTHYROIDISM A BOOKLET FOR PATIENTS AND THEIR FAMILIES A publication of the American Thyroid Association (ATA) www.thyroid.org COPYRIGHT 2013 AMERICAN THYROID ASSOCIATION THE AMERICAN THYROID ASSOCIATION
More informationHyperthyroidism & Hypothyroidism
Hyperthyroidism & Hypothyroidism TSH: 7,1 mu/l (?) Overview 1. Thyroid physiology 2. Hypothyroidism 3. Hyperthyroidism 4. Tumors 5. Case History 1-6 The Thyroid gland and its downward migration Failure
More informationVitamin D Deficiency and Thyroid Disease. Theodore C. Friedman, M.D., Ph.D.
Vitamin D Deficiency and Thyroid Disease Theodore C. Friedman, M.D., Ph.D. Vitamin D deficiency and thyroid diseases Vitamin D is an important vitamin that not only regulates calcium, but also has many
More informationNICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
More informationPatient Guide to Radioiodine Treatment For Thyrotoxicosis (Overactive Thyroid Gland or Hyperthyroidism)
Patient Guide to Radioiodine Treatment For Thyrotoxicosis (Overactive Thyroid Gland or Hyperthyroidism) Your doctor has referred you to Nuclear Medicine for treatment of your overactive thyroid gland.
More informationScreening for Thyroid Disease
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ
More informationCommon Endocrine Disorders. Gary L. Horowitz, MD Beth Israel Deaconess Medical Center Boston, MA
Common Endocrine Disorders Gary L. Horowitz, MD Beth Israel Deaconess Medical Center Boston, MA Objectives Describe the typical laboratory values for TSH and Free T4 in hypo- and hyperthyroidism Explain
More informationLakeview Endocrinology and Diabetes Consultants. 2719 N Halsted St C-1. Chicago IL 60614 P: 773 388 5685 F: 773 388 5687. www.lakeviewendocrinolgy.
Lakeview Endocrinology and Diabetes Consultants 2719 N Halsted St C-1 Chicago IL 60614 P: 773 388 5685 F: 773 388 5687 www.lakeviewendocrinolgy.com Patient information: Early menopause (premature ovarian
More informationDiabetic Emergencies. David Hill, D.O.
Diabetic Emergencies David Hill, D.O. Class Outline Diabetic emergency/glucometer training Identify the different signs of insulin shock Diabetic coma, and HHNK Participants will understand the treatment
More informationAging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone
Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent
More informationProvided by the American Venous Forum: veinforum.org
CHAPTER 3 CLOTTING DISORDERS Original authors: Edith A. Nutescu, Jessica B. Michaud, Joseph A. Caprini, Louis W. Biegler, and Robert R. McCormick Abstracted by Kellie R. Brown Introduction The normal balance
More informationUK Guidelines for the Use of Thyroid Function Tests
UK Guidelines for the Use of Thyroid Function Tests July 2006 1 Contents Guidelines development group 4 Notes on the development and use of the guidelines 5 Types of evidence and the grading of recommendations
More informationUnderstanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
More informationPrior Authorization Form
Prior Authorization Form Growth Hormone This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS/Caremark at
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationOpen the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke
Open the Flood Gates Urinary Obstruction and Kidney Stones Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke Nephrology vs. Urology Nephrologist a physician who has been trained in the diagnosis
More informationEndocrine Responses to Resistance Exercise
chapter 3 Endocrine Responses to Resistance Exercise Chapter Objectives Understand basic concepts of endocrinology. Explain the physiological roles of anabolic hormones. Describe hormonal responses to
More informationtestosterone_pellet_implantation_for_androgen_deficiency_in_men 10/2015 N/A 11/2016 10/2015 This policy is not effective until December 30, 2015
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency_in_men
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationUnderstanding Hypoventilation and Its Treatment by Susan Agrawal
www.complexchild.com Understanding Hypoventilation and Its Treatment by Susan Agrawal Most of us have a general understanding of what the term hyperventilation means, since hyperventilation, also called
More informationRecovering with T3 - by Paul Robinson. Introduction
Recovering with T3 - by Paul Robinson Introduction I am not a professional writer. Neither am I a doctor, a medical researcher or a biochemist. I am simply a man who has had his life derailed by thyroid
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More informationThyroid Problems after Childhood Cancer
Thyroid Problems after Childhood Cancer Some people who were treated for cancer during childhood may develop endocrine (hormone) problems as a result of changes in the function of a complex system of glands
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationD. Vitamin D. 1. Two main forms; vitamin D2 and D3
D. Vitamin D. Two main forms; vitamin D2 and D3 H H D3 - Cholecalciferol D2 - Ergocalciferol Technically, vitamin D is not a vitamin. It is the name given to a group of fat-soluble prohormones (substances
More informationDisease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
More informationEndocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER
Endocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER 80% of children and adults with FA have an endocrine abnormality Endocrine cells make a hormone (message) Carried in bloodstream
More informationSection 2. Overview of Obesity, Weight Loss, and Bariatric Surgery
Section 2 Overview of Obesity, Weight Loss, and Bariatric Surgery What is Weight Loss? How does surgery help with weight loss? Short term versus long term weight loss? Conditions Improved with Weight Loss
More informationIRON METABOLISM DISORDERS
IRON METABOLISM DISORDERS ANEMIA Definition Decrease in the number of circulating red blood cells Most common hematologic disorder by Most common hematologic disorder by far 1 Blood loss ANEMIA Causes
More informationFelimazole 5 mg Coated Tablet
.. CARTON TEXT - FRONT PANEL PRESCRIPTION ANIMAL REMEDY READ SAFETY DIRECTIONS BEFORE OPENING OR USING KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY RLP Approved Felimazole 5 mg Coated Tablet
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationInterpretation of Laboratory Values
Interpretation of Laboratory Values Konrad J. Dias PT, DPT, CCS Overview Electrolyte imbalances Renal Function Tests Complete Blood Count Coagulation Profile Fluid imbalance Sodium Electrolyte Imbalances
More informationInpatient Heart Failure Management: Risks & Benefits
Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationThyroid pathology in the Presence of antiviral treatment of chronic hepatitis C. Professor Nikitin Igor G Russian State Medical University MOSCOW
Thyroid pathology in the Presence of antiviral treatment of chronic hepatitis C Professor Nikitin Igor G Russian State Medical University MOSCOW The structure of the side effects associated with antiviral
More informationPaxil/Paxil-CR (paroxetine)
Generic name: Paroxetine Available strengths: 10 mg, 20 mg, 30 mg, 40 mg tablets; 10 mg/5 ml oral suspension; 12.5 mg, 25 mg, 37.5 mg controlled-release tablets (Paxil-CR) Available in generic: Yes, except
More informationCommon Surgical Procedures in the Elderly
Common Surgical Procedures in the Elderly From hip and knee replacements to cataract and heart surgery, America s elderly undergo 20% of all surgical procedures. For a group that comprises only 13% of
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Euthyrox 50 microgram tablets Euthyrox 100 microgram tablets Levothyroxine sodium
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Euthyrox 50 microgram tablets Euthyrox 100 microgram tablets Levothyroxine sodium Read all of this leaflet carefully before you start taking this
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationEndocrine Causes of Chronic Fatigue Syndrome (CFS)/Chronic Fatigue Immune. Deficiency Syndrome (CFIDS):
1 Endocrine Causes of Chronic Fatigue Syndrome (CFS)/Chronic Fatigue Immune Deficiency Syndrome (CFIDS): A Brief Guide for Patients and Primary Care Physicians Theodore C. Friedman and Camille Kimball
More information1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net
1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net Diabetes Mellitus (in cats) Diabetes, sugar Affected Animals: Most diabetic cats are older than 10 years of age when they are
More informationEndocrinology: Interpreting Endocrine Tests
Why are we talking about this? Endocrinology: Interpreting Endocrine Tests GP Refresher course 2012 Maralyn Druce Senior Lecturer / Consultant Centre for Endocrinology Endocrine telephone advice clinic
More informationLiver Function Essay
Liver Function Essay Name: Quindoline Ntui Date: April 20, 2009 Professor: Dr. Danil Hammoudi Class: Anatomy and Physiology 2 Liver function The human body consist of many highly organize part working
More informationMeeting the Needs of Aging Persons. Aging in Individuals with a
Meeting the Needs of Aging Persons with Developmental Disabilities Cross Network Collaboration for Florida Aging in Individuals with a Developmental Disability Module 3 Based on ADRC training developed
More informationGP Guidance: Management of nutrition following bariatric surgery
GP Guidance: Management of nutrition following bariatric surgery Introduction Patients who are morbidly obese will have struggled with their weight for many years before going forward for bariatric surgery.
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationAmylase and Lipase Tests
Amylase and Lipase Tests Also known as: Amy Formal name: Amylase Related tests: Lipase The Test The blood amylase test is ordered, often along with a lipase test, to help diagnose and monitor acute or
More informationBio-Identical Hormone FAQ s
Bio-Identical Hormone FAQ s What are bio-identical hormones? They are derived from a natural plant source and professionally compounded to be biologically identical to human form of estradiol and testosterone.
More informationACLS Cardiac Arrest Algorithm Neumar, R. W. et al. Circulation 2010;122:S729-S767
ACLS Cardiac Arrest Algorithm Neumar, R. W. et al. Circulation 2010;122:S729-S767 Copyright 2010 American Heart Association ACLS Cardiac Arrest Circular Algorithm Neumar, R. W. et al. Circulation 2010;122:S729-S767
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationPrevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus
Prevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus Hypogonadism is defined as deficient or absent male gonadal function
More information